Wegovy vs Zepbound: Both FDA-Approved for Weight Loss

At a Glance: Wegovy vs. Zepbound

Clinical data from separate trials — not direct head-to-head. Prices approximate and subject to change. Verify with manufacturer or pharmacy.

How They Work: Different Mechanisms, Shared Goal

Wegovy (semaglutide) is a GLP-1 receptor agonist. It activates GLP-1 receptors to reduce appetite, slow gastric emptying, suppress glucagon, and stimulate glucose-dependent insulin secretion. It is structurally similar to human GLP-1 but modified for a weekly half-life.

Zepbound (tirzepatide) activates both GLP-1 and GIP receptors. GIP is the other major incretin hormone, and its receptors are found in the pancreas, brain, and adipose tissue. The dual activation is believed to produce more pronounced metabolic and appetite-suppression effects than GLP-1 receptor agonism alone — though the precise additive contribution of GIP in the overall clinical effect continues to be studied.

Both medications require ongoing use to maintain their effect. Clinical trial data (STEP 4 for Wegovy, SURMOUNT-4 for Zepbound) shows that stopping either medication leads to significant weight regain over time, suggesting these are chronic treatments rather than short-course interventions.

Clinical Efficacy: STEP vs. SURMOUNT

Both were studied in rigorous, large-scale clinical trials specifically for weight management:

Wegovy — STEP Trials

• STEP 1 (no diabetes, n=1,961): ~14.9% avg weight reduction at 68 weeks
• STEP 3 (with intensive lifestyle intervention): ~16% avg weight reduction
• SELECT trial: Wegovy also demonstrated reduced risk of major cardiovascular events in adults with obesity/overweight and established CVD

Zepbound — SURMOUNT Trials

• SURMOUNT-1 (no diabetes, n=2,539): ~20.9% avg at 15mg, ~19.5% at 10mg at 72 weeks
• SURMOUNT-2 (with T2D): ~15.7% avg weight reduction at highest dose

Caveat: STEP and SURMOUNT were separate studies with different populations, trial durations, and measurement periods. They are not direct head-to-head comparisons. The higher numerical averages seen with tirzepatide do not mean every person will lose more weight with Zepbound than Wegovy — individual responses vary widely. No large-scale direct comparison trial has been published as of this writing.

Dosing and Escalation

Both medications follow a gradual dose escalation to minimize gastrointestinal side effects. Both are once-weekly subcutaneous injections. The escalation period is approximately 16 weeks for both before reaching the target maintenance dose.

Wegovy maintenance dose: 2.4 mg weekly. Zepbound maintenance doses: 10 mg or 15 mg weekly (clinician-determined). Both have auto-injector pen delivery systems.

Side Effect Profiles

Both medications share similar common side effects, reflecting their shared GLP-1 receptor activation:

• Nausea (most common, typically during dose escalation)
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain

Both carry class-label warnings about the risk of thyroid C-cell tumors (based on animal studies; human relevance uncertain), pancreatitis, hypoglycemia (particularly with concomitant insulin use), acute kidney injury, and hypersensitivity reactions. For a full safety overview, see our GLP-1 safety guide and side effects guide.

Cost and Insurance Coverage

Both Wegovy and Zepbound are approved for the same indication (weight management), which means both face similar insurance coverage challenges. Weight-management medications are less consistently covered than diabetes medications across commercial insurance plans.

List price comparison: Wegovy is generally priced higher (~$1,300–$1,450/month) than Zepbound (~$1,000–$1,100/month). Both manufacturers offer savings programs for eligible commercially insured patients. Eli Lilly has also offered self-pay vial options for Zepbound. See our GLP-1 cost guide, Wegovy cost guide, and Zepbound cost guide for full details. Always verify current pricing with the manufacturer or your pharmacy.